Severe Eosinophilic Asthma (SEA)
Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.
Er du ikke helsepersonell? Besøk våre hjemmesider
Er du ikke helsepersonell?
Besøk gjerne våre sider for publikum.
59
Nucala is the anti-IL-5 therapy that is approved for the treatment of 4 eosinophilic diseases.1
References
Nucala is a trademark of the GSK group of companies
PM-NO-MPL-WCNT-230001 June 2023